Roche: CE marking in ovarian cancer
(CercleFinance.com) - Roche announced on Monday that it has received CE marking for Ventana as a companion diagnostic test for the treatment of ovarian cancer patients with Elahere, the new antibody-drug conjugate from the American company AbbVie.
This system thus becomes the first immunohistochemistry (IHC) test available in Europe to identify patients likely to benefit from this targeted treatment for epithelial carcinomas.
Elahere is a conjugated antibody, which couples chemotherapy molecules with an antibody, to specifically target FOLR1-positive ovarian cancers resistant to conventional cisplatin-based chemotherapies.
With a death rate of 4.7%, ovarian cancer is the eighth most fatal cancer for women worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This system thus becomes the first immunohistochemistry (IHC) test available in Europe to identify patients likely to benefit from this targeted treatment for epithelial carcinomas.
Elahere is a conjugated antibody, which couples chemotherapy molecules with an antibody, to specifically target FOLR1-positive ovarian cancers resistant to conventional cisplatin-based chemotherapies.
With a death rate of 4.7%, ovarian cancer is the eighth most fatal cancer for women worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.